Drs Joseph Mikhael and Shaji Kumar discuss the future of multiple myeloma, including enhanced diagnostics for detecting myeloma, frontline therapy, and durable responses.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002718. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Multiple Myeloma https://emedicine.medscape.com/article/204369-overview

Updated Diagnostic Criteria and Staging System for Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/27249749/

Mass Spectrometry for the Evaluation of Monoclonal Proteins in Multiple Myeloma and Related Disorders: An International Myeloma Working Group Mass Spectrometry Committee Report https://pubmed.ncbi.nlm.nih.gov/33563895/

Multiple Myeloma Imaging https://emedicine.medscape.com/article/391742-overview

Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis https://pubmed.ncbi.nlm.nih.gov/34299097/

Monoclonal Gammopathy of Undetermined Significance https://www.ncbi.nlm.nih.gov/books/NBK507880/

Primary Plasma Cell Leukemia: Consensus Definition by the International Myeloma Working Group According to Peripheral Blood Plasma Cell Percentage https://pubmed.ncbi.nlm.nih.gov/34857730/

Advancing MRD Detection in Multiple Myeloma: Technologies, Applications, and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/40214184/

Genomic Landscape of Multiple Myeloma and Its Precursor Conditions https://pubmed.ncbi.nlm.nih.gov/40399554/

Quadruplet Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/39348665/

Subcutaneous Daratumumab (Dara) + Bortezomib/Lenalidomide/Dexamethasone (VRd) With Dara + Lenalidomide (DR) Maintenance in Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Sustained Minimal Residual Disease Negativity in the Phase 3 PERSEUS Trial https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.7501

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial https://pubmed.ncbi.nlm.nih.gov/39841461/

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant Is Not a Medically Suitable Treatment https://www.clinicaltrials.gov/study/NCT05561387

Cytokine Release Syndrome and Associated Neurotoxicity in Cancer Immunotherapy https://pubmed.ncbi.nlm.nih.gov/34002066/

The Role of CELMoD Agents in Multiple Myeloma https://pmc.ncbi.nlm.nih.gov/articles/PMC12399888/

Phase 2 Study of Talquetamab + Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma and Extramedullary Disease: REDIRECTT-1 https://library.ehaweb.org/eha/2025/eha2025-congress/4173809/shaji.kumar.phase.2.study.of.talquetamab.2B.teclistamab.in.patients.with.html

Discovery of a Novel Class NSD2 Inhibitor for Multiple Myeloma With t(4;14) https://pubmed.ncbi.nlm.nih.gov/40949769/

Long-Term (≥5 Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel (Cilta-Cel) in CARTITUDE-1 Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.7507